LiverCompass for Patients
A patient-facing companion that takes a hepatocellular carcinoma diagnosis report and translates it into plain language with a personalized question list, treatment-option overview, and second-opinion checklist.
Newly diagnosed liver cancer patients and their adult family caregivers
- Diagnosis decoder that turns oncology jargon into a plain-language summary with severity context
- Treatment options overview ranked by the patient's specific stage, with pros, cons, and typical side effects
- Doctor-visit prep: generates the top 10 questions to ask the oncologist at the next appointment
- Second-opinion packet export that packages the case for sharing with another cancer center
Clinical reasoning LLMs for HCC have just crossed the threshold where they match or beat attending physicians on treatment recommendations, but patients still get only a 15-minute consult to absorb a life-changing plan.
HCC is the 4th leading cause of cancer death globally with 5-year survival below 30% and ~25% cure rate, creating a large, emotionally-charged newly-diagnosed population that struggles to absorb treatment plans in short consults.An Open-Access, Interactive Decision-Support Tool to Facilitate ... ↗Hepatocellular carcinoma: Epidemiology, diagnosis and treatment ↗
Direct competitors already exist: CancerCompanion explicitly translates reports and guides through treatment in plain language, CareCompanion AI, Wizey, and a liver-specific LiverCareLine all address the same patient-facing report-translation pain point.Cancer Campanion ↗CareCompanion AI — Cancer Care App for Patients & Caregivers ↗LiverCareLine — Your Liver Health Companion ↗AI Medical Report & Lab Result Analyzer | Wizey ↗
No public willingness-to-pay or pricing evidence surfaced for this niche; cancer patients typically face financial strain, and HCC-specific need is acute/low-frequency, making B2C subscription monetization difficult without payer or pharma partnerships.Wizey ↗CareCompanion AI ↗
HCC incidence has risen ~75% from 1990–2015, accounts for 85–90% of liver cancers, and 5-year survival remains below 30% — the structural need for patient-facing decision support will persist as treatment options (immunotherapy combos, TACE, transplant) continue to expand and complicate choices.Hepatocellular carcinoma: updates on epidemiology, surveillance ... ↗An Open-Access, Interactive Decision-Support Tool to Facilitate ... ↗
Technically buildable with existing LLMs and well-documented clinical frameworks (BCLC staging, ESMO/NCCN guidelines), but regulatory risk (medical information claims in many jurisdictions), liability exposure, and the need for clinical validation are real barriers that push it below trivial-to-build.Hepatocellular Carcinoma: A Guide for Patients | ESMO ↗